



High-Altitude Medicine

Current trends and prevention

FMF - 2014
Eric Mercier, MD, MSc

3

Objectives



CIWEC clinic

Nepal



Acclimatization process

Altitude-related diseases

Prevention | Treatment

Plan

Acclimatization process

Altitude-related diseases

Prevention | Treatment

No conflicts of interest

Plan

Acclimatization

Series of integrated adaptations that take place at high altitude, which tend to restore the oxygen pressure toward normal sea levels despite the lowered PO₂

Acclimatization

Barometric
pressure

FiO₂

Inspired oxygen
pressure
(PiO₂)

Sea level :

$$760 \text{ mmHg} \times 0.21 =$$

Barometric
pressure

FiO₂

Inspired oxygen
pressure
(PiO₂)

Sea level :

$$760 \text{ mmHg} \times 0.21 = 160 \text{ mmHg}$$

Barometric
pressure

FiO₂

Inspired oxygen
pressure
(PiO₂)

Sea level :

$$760 \text{ mmHg} \times 0.21 = 160 \text{ mmHg}$$

Everest
summit
(8848 m) :

$$253 \text{ mmHg} \times 0.21 =$$

Barometric
pressure

FiO₂


Inspired oxygen
pressure
(PiO₂)

Sea level :


$$760 \text{ mmHg} \times 0.21 = 160 \text{ mmHg}$$

Everest
summit
(8848 m) :

$$253 \text{ mmHg} \times 0.21 = 53 \text{ mmHg}$$



of Oxygen in
air at sea level



of Oxygen in
air at altitude

ORIGINAL ARTICLE


Arterial Blood Gases and Oxygen Content in Climbers on Mount Everest

Michael P.W. Grocott, M.B., B.S., Daniel S. Martin, M.B., Ch.B.,
Denny Z.H. Levett, B.M., B.Ch., Roger McMorrow, M.B., B.Ch.,
Jeremy Windsor, M.B., Ch.B., and Hugh E. Montgomery, M.B., B.S., M.D.,
for the Caudwell Xtreme Everest Research Group*

ORIGINAL ARTICLE

Arterial Blood Gases and Oxygen Content
in Climbers on Mount Everest

Michael P.W. Grocott, M.B., B.S., Daniel S. Martin, M.B., Ch.B.,
Denny Z.H. Levett, B.M., B.Ch., Roger McNamee, M.B., B.Ch.,
Jeremy Windsor, M.B., Ch.B., and Hugh E. Montgomery, M.B., B.S., M.D.,
for the Caudwell Xtreme Everest Research Group*



ORIGINAL ARTICLE

Arterial Blood Gases and Oxygen Content
in Climbers on Mount Everest

Michael P.W. Grocott, M.B., B.S., Daniel S. Martin, M.B., Ch.B.,
Denny Z.H. Levett, B.M., B.Ch., Roger McNamee, M.B., B.Ch.,
Jeremy Windsor, M.B., Ch.B., and Hugh E. Montgomery, M.B., B.S., M.D.,
for the Caudwell Xtreme Everest Research Group*

ORIGINAL ARTICLE

Arterial Blood Gases and Oxygen Content
in Climbers on Mount Everest

Michael P.W. Grocott, M.B., B.S., Daniel S. Martin, M.B., Ch.B.,
Denny Z.H. Levett, B.M., B.Ch., Roger McNamee, M.B., B.Ch.,
Jeremy Windsor, M.B., Ch.B., and Hugh E. Montgomery, M.B., B.S., M.D.,
for the Caudwell Xtreme Everest Research Group*

Table 2. Arterial Blood Gas Measurements and Calculated Values for Pulmonary Gas Exchange from Four Subjects at an Altitude of 8400 m, during Descent from the Summit of Mount Everest.*

Variable	Subject No.				Group Mean
	1	2	3	4	
pH	7.55	7.45	7.52	7.60	7.53
PaO ₂ (mm Hg)†	29.5	19.1	21.0	28.7	24.6
PaCO ₂ (mm Hg)†	12.3	15.7	15.0	10.3	13.3
Bicarbonate (mmol/liter)‡	10.5	10.67	11.97	9.87	10.8
Base excess of blood‡	-6.3	-9.16	-6.39	-5.71	-6.9
Lactate concentration (mmol/liter)	2.0	2.0	2.9	1.8	2.2
SaO ₂ (%)‡	68.1	34.4	43.7	69.7	54.0
Hemoglobin (g/dl)§	20.2	18.7	18.8	19.4	19.3
Respiratory exchange ratio¶	0.81	0.74	0.72	0.70	0.74
PAO ₂ — mm Hg†**	32.4	26.9	27.4	33.2	30.0
Alveolar–arterial oxygen difference — mm Hg†	2.89	7.81	6.44	4.51	5.41

ORIGINAL ARTICLE

Arterial Blood Gases and Oxygen Content
in Climbers on Mount Everest

Michael P.W. Grocott, M.B., B.S., Daniel S. Martin, M.B., Ch.B.,
Denny Z.H. Levett, B.M., B.Ch., Roger McNamee, M.B., B.Ch.,
Jeremy Windsor, M.B., Ch.B., and Hugh E. Montgomery, M.B., B.S., M.D.,
for the Caudwell Xtreme Everest Research Group*

Table 2. Arterial Blood Gas Measurements and Calculated Values for Pulmonary Gas Exchange from Four Subjects at an Altitude of 8400 m, during Descent from the Summit of Mount Everest.*

Variable	Subject No.				Group Mean
	1	2	3	4	
pH	7.55	7.45	7.52	7.60	7.53
PaO ₂ (mm Hg)†	29.5	19.1	21.0	28.7	24.6
PaCO ₂ (mm Hg)†	12.3	15.7	15.0	10.3	13.3
Bicarbonate (mmol/liter)‡	10.5	10.67	11.97	9.87	10.8
Base excess of blood‡	-6.3	-9.16	-6.39	-5.71	-6.9
Lactate concentration (mmol/liter)	2.0	2.0	2.9	1.8	2.2
SaO ₂ (%)‡	68.1	34.4	43.7	69.7	54.0
Hemoglobin (g/dl)§	20.2	18.7	18.8	19.4	19.3
Respiratory exchange ratio¶	0.81	0.74	0.72	0.70	0.74
PAO ₂ — mm Hg†**	32.4	26.9	27.4	33.2	30.0
Alveolar–arterial oxygen difference — mm Hg†	2.89	7.81	6.44	4.51	5.41

ORIGINAL ARTICLE

Arterial Blood Gases and Oxygen Content
in Climbers on Mount Everest

Michael P.W. Grocott, M.B., B.S., Daniel S. Martin, M.B., Ch.B.,
Denny Z.H. Levett, B.M., B.Ch., Roger McNamee, M.B., B.Ch.,
Jeremy Windsor, M.B., Ch.B., and Hugh E. Montgomery, M.B., B.S., M.D.,
for the Caudwell Xtreme Everest Research Group*

Table 2. Arterial Blood Gas Measurements and Calculated Values for Pulmonary Gas Exchange from Four Subjects at an Altitude of 8400 m, during Descent from the Summit of Mount Everest.*

Variable	Subject No.				Group Mean
	1	2	3	4	
pH	7.55	7.45	7.52	7.60	7.53
PaO ₂ (mm Hg)†	29.5	19.1	21.0	28.7	24.6
PaCO ₂ (mm Hg)†	12.3	15.7	15.0	10.3	13.3
Bicarbonate (mmol/liter)†	10.5	10.67	11.97	9.87	10.8
Base excess of blood‡	-6.3	-9.16	-6.39	-5.71	-6.9
Lactate concentration (mmol/liter)	2.0	2.0	2.9	1.8	2.2
SaO ₂ (%)‡	68.1	34.4	43.7	69.7	54.0
Hemoglobin (g/dl)§	20.2	18.7	18.8	19.4	19.3
Respiratory exchange ratio¶	0.81	0.74	0.72	0.70	0.74
PAO ₂ — mm Hg†**	32.4	26.9	27.4	33.2	30.0
Alveolar–arterial oxygen difference — mm Hg†	2.89	7.81	6.44	4.51	5.41

ORIGINAL ARTICLE

Arterial Blood Gases and Oxygen Content
in Climbers on Mount Everest

Michael P.W. Grocott, M.B., B.S., Daniel S. Martin, M.B., Ch.B.,
Denny Z.H. Levett, B.M., B.Ch., Roger McNamee, M.B., B.Ch.,
Jeremy Windsor, M.B., Ch.B., and Hugh E. Montgomery, M.B., B.S., M.D.,
for the Caudwell Xtreme Everest Research Group*

Table 2. Arterial Blood Gas Measurements and Calculated Values for Pulmonary Gas Exchange from Four Subjects at an Altitude of 8400 m, during Descent from the Summit of Mount Everest.*

Variable	Subject No.				Group Mean
	1	2	3	4	
pH	7.55	7.45	7.52	7.60	7.53
PaO ₂ (mm Hg)†	29.5	19.1	21.0	28.7	24.6
PaCO ₂ (mm Hg)†	12.3	15.7	15.0	10.3	13.3
Bicarbonate (mmol/liter)‡	10.5	10.67	11.97	9.87	10.8
Base excess of blood‡	-6.3	-9.16	-6.39	-5.71	-6.9
Lactate concentration (mmol/liter)	2.0	2.0	2.9	1.8	2.2
SaO ₂ (%)‡	68.1	34.4	43.7	69.7	54.0
Hemoglobin (g/dl)§	20.2	18.7	18.8	19.4	19.3
Respiratory exchange ratio¶	0.81	0.74	0.72	0.70	0.74
PAO ₂ — mm Hg†**	32.4	26.9	27.4	33.2	30.0
Alveolar–arterial oxygen difference — mm Hg†	2.89	7.81	6.44	4.51	5.41

Hypoxic ventilatory response

Altitude-related diseases



AMS

HACE

HAPE

Acute mountain sickness (AMS)

Table 2: Lake Louise Consensus
Definition For The Diagnosis Of AMS

- An individual is at or above 2500 m above sea level *and*
 - A headache is present *and*
 - An individual has any one of the following:
 - GI Symptoms (nausea, vomiting, anorexia)
 - Sleep symptoms (insomnia, difficulty sleeping)
 - Fatigue/weakness
 - Dizziness/lightheadedness
-

Acute mountain sickness (AMS)

Table 2: Lake Louise Consensus
Definition For The Diagnosis Of AMS

- An individual is at or above 2500 m above sea level *and*
 - A headache is present *and*
 - An individual has any one of the following:
 - GI Symptoms (nausea, vomiting, anorexia)
 - Sleep symptoms (insomnia, difficulty sleeping)
 - Fatigue/weakness
 - Dizziness/lightheadedness
-



**Table 7: The Lake Louise Consensus
Criteria For HACE**

The presence of a change in mental status or ataxia
in a person with AMS

OR

The presence of both a change in mental status and
ataxia in a person without AMS

High-altitude cerebral edema **(HACE)**

**Table 4: The Lake Louise Consensus
Definition Of HAPE Includes¹¹**

At least two of the following symptoms:

- Dyspnea at rest
- Cough
- Weakness or decreased exercise performance
- Chest tightness or congestion

And two of the following signs:

- Crackles or wheezing in at least one lung field
 - Central cyanosis
 - Tachypnea
 - Tachycardia
-

High-altitude pulmonary edema (HAPE)

**Table 4: The Lake Louise Consensus
Definition Of HAPE Includes¹¹**

At least two of the following symptoms:

- Dyspnea at rest
- Cough
- Weakness or decreased exercise performance
- Chest tightness or congestion

And two of the following signs:

- Crackles or wheezing in at least one lung field
 - Central cyanosis
 - Tachypnoea
 - Tachycardia
-



High-altitude pulmonary edema (HAPE)

Most of the **deaths**
are caused
by a **trauma**

Prevention | Treatment

Planification

Medication

Technologies

Planification

Planification

Single
MOST
important
factor

Planification

Before

The **time allowed** to complete your trip
MUST be **longer** than the expected one

It is IMPOSSIBLE to save a significant amount of
money without compromising your **safety**

Case report

Case report

Day I (3440 m) : Did not feel good

Case report

Day 1 (3440 m) : Did not feel good

Day 2 (3860 m) : Continued to climb, was feeling worst

Case report

Day 1 (3440 m) : Did not feel good

Day 2 (3860 m) : Continued to climb, was feeling worst

Day 3 (4410 m) : Used a horse to continue her ascension

Case report

Day 1 (3440 m) : Did not feel good

Day 2 (3860 m) : Continued to climb, was feeling worst

Day 3 (4410 m) : Used a horse to continue her ascension

Day 4 : Was not able to walk

Fell off the horse

Broke her wrist

Rescuers were called

Planification

During

Planification

During

Respect your body and
pay close attention to your **symptoms**

Planification

During

Respect your body and
pay close attention to your **symptoms**

Your position within the group should be the
same during the whole trip

Planification

During

Climb high, sleep low

Respect your body and
pay close attention to your symptoms

Your position within the group should be the
same during the whole trip

Planification

REVIEW ARTICLE


Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness

Andrew M. Luks, MD; Scott E. McIntosh, MD, MPH; Colin K. Grissom, MD; Paul S. Auerbach, MD, MS;
George W. Rodway, PhD, APRN; Robert B. Schoene, MD; Ken Zafren, MD; Peter H. Hackett, MD

From the Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA (Drs Luks and Schoene); Division of Emergency Medicine, University of Utah, Salt Lake City, UT (Dr McIntosh); Division of Pulmonary and Critical Care Medicine, Intermountain Medical Center and the University of Utah, Salt Lake City, UT (Dr Grissom); Department of Surgery, Division of Emergency Medicine, Stanford University School of Medicine, Palo Alto, CA (Drs Auerbach and Zafren); College of Nursing and School of Medicine, University of Utah, Salt Lake City, UT (Dr Rodway); Bozeman Deaconess Hospital, Bozeman, MT (Dr Schoene); Himalayan Rescue Association, Kathmandu, Nepal (Dr Zafren); Division of Emergency Medicine, Altitude Research Center, University of Colorado Denver School of Medicine, Denver, CO (Dr Hackett); and Institute for Altitude Medicine, Telluride, CO (Dr Hackett).

1. Sleep the first night \leq 2750 meters
2. Climb a maximum of 500 meters per day
3. Sleep an extra night at the same altitude every 1000 meters

AMS



stay

HACE



go down

HAPE



go down*


Medication

Medication

Acetazolamide

NSAID


Dexamethasone




AMS/HACE

Nifedipine
5-phosphodiesterase inhibitors

Azithromycin



HAPE



Respiratory
stimulant

Acetazolamide

RESEARCH

**Identifying the lowest effective dose of acetazolamide
for the prophylaxis of acute mountain sickness:
systematic review and meta-analysis** OPEN ACCESS**AMS/HACE**

Prophylaxis : 125 mg PO BID NNT = 8
Treatment : 500 mg PO BID

Acetazolamide

ORIGINAL RESEARCH

Altitude Sickness in Climbers and Efficacy of NSAIDs Trial
(ASCENT): Randomized, Controlled Trial of Ibuprofen
Versus Placebo for Prevention of Altitude Illness

Jeffrey H. Gertsch, MD; Bryan Corbett, MD; Peter S. Holck, PhD; Allison Mulcahy, MD; Melanie Watts, MD;
Nathan Thomas Stillwagon, MD; Amanda Morgan Casto, MD; Charles Hessel Abramson, MD;
Charles Peter Aloysius Vaughan, MD; Christopher Macguire, MD; Neda Nicole Farzan, MD;
Baotran Nguyen Vo, MD; Rebecca Jean Norvelle, MD; Kerstin May, MD; Jessica Elizabeth Holly, MD;
Hillary Irons, MD; Aaron Michael Stutz, MD; Pradip Chapagain, MD; Siddhartha Yadav, MD;
Matiram Pun, MD; Jeremy Farrar, BSc, MBBS, FRCP, DPhil, OBE; Buddha Basnyat, MD, MSc, FRCP(E)

AMS/HACE

Ibuprofen most studied

Efficacy ?

Prevention - Maybe
Treatment - Yes

NSAID

Only a few studies

Dexamethasone

AMS/HACE

Only a few studies

Efficacy proven for
prevention and treatment of AMS

Standard of care for HACE

Dexamethasone

AMS/HACE

Only a few studies

Efficacy proven for
prevention and treatment of AMS

Standard of care for HACE

Prevention of HAPE

Dexamethasone

AMS/HACE

HAPE

ORIGINAL RESEARCH

Nifedipine for the Treatment of High Altitude Pulmonary Edema

Rajesh Deshwal, MD, FHM; Mohd Iqbal, MD; Sidhant Basnet, MBBS

From the Department of Medicine, Military Hospital, Gangtok, Sikkim, India (Drs Deshwal, Iqbal, and Basnet).

Nifedipine

HAPE

ORIGINAL RESEARCH

Nifedipine for the Treatment of High Altitude Pulmonary Edema

Rajesh Deshwal, MD, FHM; Mohd Iqbal, MD; Sidhant Basnet, MBBS

From the Department of Medicine, Military Hospital, Gangtok, Sikkim, India (Drs Deshwal, Iqbal, and Basnet).

Nifedipine

Controversial

HAPE

ORIGINAL RESEARCH

Nifedipine for the Treatment of High Altitude Pulmonary Edema

Rajesh Deshwal, MD, FHM; Mohd Iqbal, MD; Sidhant Basnet, MBBS

From the Department of Medicine, Military Hospital, Gangtok, Sikkim, India (Drs Deshwal, Iqbal, and Basnet).

Nifedipine

Controversial

No role in prevention
Maybe for treatment

HAPE

5-phosphodiesterase inhibitors

HAPE

Only one small RCT

**5-phosphodiesterase
inhibitors**

HAPE

Only one small RCT

Maybe for prevention
Maybe for treatment

5-phosphodiesterase
inhibitors

HAPE

Azithromycin

Absolutely no studies
but...

HAPE


Azithromycin

Absolutely no studies
but...

many clinicians **think it works**

Other medications

Furosemide
Prednisone
Salbutamol
Magnesium
Ginko bilboa



Avoid all substances that **may**
interfere with the
hypoxic ventilatory response

Technologies

Hypobaric chamber



Hypobaric chamber



NO scientific evidence
Dangerous !

Pulse oximetry



HIGH ALTITUDE MEDICINE & BIOLOGY
Volume 12, Number 2, 2011
© Mary Ann Liebert, Inc.
DOI: 10.1089.ham.2011.0013



Pulse Oximetry at High Altitude

Andrew M. Luks and Erik R. Swenson

Pulse oximetry



HIGH ALTITUDE MEDICINE & BIOLOGY
Volume 12, Number 2, 2011
© Mary Ann Liebert, Inc.
DOI: 10.1089.ham.2011.0013



Pulse Oximetry at High Altitude

Andrew M. Luks and Erik R. Swenson

NO scientific evidence

Inaccurate
No correlation SpO₂ - HAPE

REVIEW ARTICLE

Using Ultrasound Lung Comets in the Diagnosis of High Altitude Pulmonary Edema: Fact or Fiction?

Yashvi Wimalasena, BM, FCEM, DiMM; Jeremy Windsor, MBChB, DCH, FCARCS;
Mark Edsell, MBChB, FRCA, FFICM

From the Emergency Department, University Hospitals Coventry and Warwickshire (Dr Wimalasena) and the Birmingham Medical Research Expeditionary Society (Drs Wimalasena and Edsell), Birmingham; and University College London (Dr Windsor) and St George's Hospital London (Dr Edsell), UK.

Ultrasound

REVIEW ARTICLE

Using Ultrasound Lung Comets in the Diagnosis of High Altitude Pulmonary Edema: Fact or Fiction?

Yashvi Wimalasena, BM, FCEM, DiMM; Jeremy Windsor, MBChB, DCH, FCARCS;
Mark Edsell, MBChB, FRCA, FFICM

From the Emergency Department, University Hospitals Coventry and Warwickshire (Dr Wimalasena) and the Birmingham Medical Research Expeditionary Society (Drs Wimalasena and Edsell), Birmingham; and University College London (Dr Windsor) and St George's Hospital London (Dr Edsell), UK.

Ultrasound Maybe

Sensitive for HAPE
Specific ?

Eric-based medicine

Eric-based medicine

Planification is the key

Eric-based medicine

Planification is the key

Respect the ascension rate

Eric-based medicine

Planification is the key

Respect the ascension rate

Avoid sedatives

What to bring with you

What to bring with you

**Acetazolamide
Dexamethasone
Nifedipine ?
Cipro/azithro
Immobilisation kit**

Questions ?



Thank you